Objectives: This study explored whether TALENs-mediated non-homologous end joining (NHEJ) targeting the mutation site can correct the aberrant β-globin RNA splicing, and ameliorate the β-thalassaemia phenotype in β 654 mice.
Material and methods: TALENs vectors targeted to the human β-globin gene (HBB)
IVS2-654C >T mutation in a mouse model were constructed and selected to generate 
| INTRODUC TI ON
β-thalassaemia is a genetically determined haematopoietic disorder caused by aberrant synthesis of the β-globin chain of haemoglobin.
It is a fairly common inherited disease, with approximately 1.5% of the world's population reported to be carriers, and over 40 000 children are born annually with β-thalassaemia, according to the World Health Organization estimates. 1 The clinical management of β-thalassaemia largely depends on lifelong blood transfusions and iron chelation therapy. However, in addition to increased iron absorption, transfusion therapy can lead to progressive iron accumulation and tissue damage in multiple organs, such as liver and spleen. 2 The majority of patients with β-thalassaemia still experience reduced life expectancy and a relatively poor quality of life, especially those in developing countries. At present, the best treatment option for these patients is allogeneic bone marrow transplantation, which is limited by the availability of a histocompatible donor. Thus, gene therapy represents an attractive alternative for the treatment of β-thalassaemia. 3 More than 200 mutations in the human β-globin gene (HBB) have been reported, and a large number of mutations are singlenucleotide substitutions in functional regions of HBB. 4 According to our previous study, a C→T substitution within the second intron of HBB (IVS2-654C > T, c. 316 + 654 C > T) was found to be one of the most common β-thalassaemia alleles affected in Han Chinese populations. 5 The β 654 mutation results in the generation of an aberrant 5′ donor splice site at position 652 and activation of a cryptic 3′ acceptor splice site at position 579, leading to the aberrantly spliced β-globin mRNA containing a premature termination codon.
5,6
Fortunately, our study revealed that β 654 patients were found to be able to produce approximately 15% of normal β-globin, therefore a β + rather than β 0 phenotype, 5, 6 making them suitable candidates for further exploration of various treatment options using gene therapy.
As reduced synthesis of β-globin chains results in the relative excess of α-globin chains, the degree of excess determines the severity of the disease symptoms. Therefore, one favourable approach to treat β 654 -thalassaemia is to disrupt the incorrect splicing to increase normal β-globin synthesis, and thus to balance the α/β gene expression.
Our previous study using RNAi to knock down α-globin mRNA combined with antisense RNA to reduce abnormal β 654 -globin mRNA and increase correct splicing of β-globin mRNA, demonstrated gratifying result to ameliorate the β-thalassaemia symptoms in β 654 mice. [7] [8] [9] The strategy of transferring human β-globin gene using a lentiviral vector in animal models and human patients was also implemented, which greatly relieved the anaemic complications. 10, 11 However, the potential risks of using viral vector therapy remain challenging in clinical applications. [12] [13] [14] With the rapid development of genome editing tools, such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and CRISPR/Cas9 (clustered, regularly interspaced short palindromic repeats/CRISPR-associated protein 9) systems, the mutant DNA site can be modified with increased efficiency compared to standard homologous recombination, through generation of double-strand DNA breaks (DSBs). A few pioneering studies have succeeded in targeting the HBB, both by TALENs and by CRISPR/ Cas9 in β-thalassaemia patient-specific induced pluripotent stem cells (iPSCs). [15] [16] [17] [18] [19] [20] However, the application of gene-edited iPSCs is still limited by the low efficiency of homology-directed repair (HDR) and the barrier associated with differentiation of iPSCs into sufficient number of haematopoietic cells for transplantation.
Non-homologous end joining (NHEJ), on the other hand, occurs at a much higher frequency once the DSBs are introduced into the genome when comparing to HDR. 21, 22 As the β 654 mutation is due to the change of a single nucleotide located in the intron of HBB, we anticipated that a direct deletion of the mutant site by NHEJ would disrupt the incorrectly splicing of β-globin mRNA while restoring the normal β expression. Thus, the present study utilizes TALENsmediated gene editing to target the HBB IVS2-654C > T mutations, and investigates the effect of TALENs-mediated NHEJ targeting the mutation in improve the β-thalassaemia disease symptoms in β 654 mice.
| MATERIAL S AND ME THODS

| Animals
The β 654 -thalassaemia mice were obtained from the Jackson 
| The construction of TALENs vectors
Six TALEN pairs (TALENL1-R1, TALENL1-R4, TALENL3-R1, TALENL3-R4, TALENL4-R1 and TALENL4-R4) were designed to directly target the IVS2-654 C >T mutation of the human β globin gene ( Figure 1A ), and TALENs vectors were constructed by one-step ligation using the FastTALETM TALEN Assembly kit (SIDANSAI, Shanghai, China). To enhance the expression efficiency of plasmids L4 and R4, the previous CMV promoter in the vectors was replaced by CAG promoter using restriction enzymes AvrII and SpeI, and the new vectors were named CL4 and CR4, respectively. To improve transfection efficiency, the co-expression vector pCAG-R4-IRES-L4 (CR4-I-L4) was also constructed by utilizing an internal ribosome entry site (IRES) sequence to link the two TALEN monomers. 
| Cell culture and transfection
| T7 Endonuclease I assay
Genomic DNA was extracted from cells transfected with TALEN plasmids. PCR amplifies the TALENs targeting site were performed using the primers β-L/R listed in Table S1 . After purification with QIA quick Gel Extraction Kit (Qiagen, Hilden, Germany), the products were denatured and reannealed, and finally digested with T7
Endonuclease I at 37°C for 60 minutes in a reaction volume of 20 μL.
Digested DNA was run on a 2% agarose gel. The efficiency of cleavage activity was calculated based on the relative band densities.
| Off-target analysis of TALENs-mediated genome modification
To monitor possible off-target events introduced by TALENs cleavage, potential gene regions harbouring similar recognition and cleavage sites were analysed using TAL Effector Nucleotide Targeter 2.0.
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Ten highly scored sites were selected for further analysis (Table   S2 ). PCR amplicons with the length of 500 bp to 900 bp containing potential off-target sites were amplified using the primers listed in Table S1 . The DNAs from clones transferred with co-expression vector pCAG-R4-IRES-L4 were pooled, and the potential off-target sites were amplified by PCR. The off-target cleavages were detected by the T7EI assay.
| Transgenic mice generation and screening
The co-expression vector pCAG-R4-IRES-L4 was digested with SphI were generated by mating TALENs transgenic mice with β 654 mice.
PCR was performed to screen the transgenic mice based on tail biopsy DNA samples.
| Southern blot
The TALENs transgenic founders were further confirmed by Southern blotting. In brief, 5 μg of genomic DNA obtained from transgenic to wild type (negative control) mice was digested with EcoRI, ran on an 0.8% agarose gel electrophoresis, and then transferred to a nylon membrane (Roche Applied Science, Mannheim, Germany). The samples were hybridized with a digoxigenin (DIG)-labelled probe amplified with the TALM-L/R 574 bp amplification products (Table S1 ) to produce a 3.8 kb positive hybridization signal.
| TAIL-PCR
The TALENs gene integration sites were determined by TAIL-PCR. 24 The primers used in TAIL-PCR were listed in Table S3 . Preamplification reactions were performed in 20 μL, and the primary or secondary TAIL-PCRs in 50 μL. The PCRs were performed using a nexus gradient mastercycler (Eppendorf, Eppendorf, Germany) with thermal conditions shown in Table S4 . The amplified products were analysed on 1.0% agarose gels, and single fragments were recovered from the gels and purified using a QIA quick Gel Extraction Kit (Qiagen, Hilden, Germany). Fragment sequences were determined by Sanger sequencing with primer L3426.
| RT-PCR
Total RNA was extracted using TRIzol from double heterozy- 
| Western blot
Blood samples from TALENs 
| Haematologic analysis
The peripheral blood smears and bone marrow slides from the three groups of mice (TALENs Table 1) .
Reticulocyte counts were determined by using brilliant tar cresylblue stain (BASO BA4003, Zhuhai, China).
| Histopathology
Eight-week-old mice from different experimental groups were used for tissue pathology analysis. Small pieces of tissue from liver and spleen were embedded in paraffin wax and sliced into 4 μm thick sections. Liver and spleen tissues were stained with haematoxylin and eosin (BASO BA4025, Zhuhai, China). Iron accumulation in liver tissues was determined by ferrocyanide iron staining (BASO BA4115, Zhuhai, China). Bone marrow smears were stained with Wright-Giemsa (BASO BA4017, Zhuhai, China).
The spleen coefficient was calculated as spleen mass divided by body mass.
| Statistical analysis
Statistical analysis was performed using GraphPad Prism 5. A Student's t test was used for inter-group comparisons, and P values < .05 were considered significant.
| RE SULTS
| TALENs-mediated deletion of the HBB
IVS2-654 C > T mutation
To disrupt incorrect splicing in the HBB IVS2 that underlies the β 654 -thalassaemia, TALENs vectors were designed to directly target the IVS2-654 C > T mutation ( Figure 1A,B) . The activity of these among all these vectors by the T7EI assay ( Figure 1D ), and was selected for further experiments. PCR products amplifying the intron 2 of HBB were cloned into the T-vector, and 40 clones were randomly selected for Sanger sequencing. Both additions and deletions of the nucleotides were detected (summarized in Figure 1E ), and 50% of these clones showed successfully disruption of the target locus. No large fragment deletion was observed around the HBB IVS2-654 site.
Whole genome sequence was searched using the software TAL Efector Nusleotide Gargeter 2.0 to identify possible off-target sites.
A total of 6732 predicted off-target sites were obtained and the 10
with the highest scores were selected for further analysis by PCR amplification followed by the T7EI assay. HBB target site was used as the control. None of the 10 regions showed evidence of off-target cleavage.
| Generation and characterization of TALENs
TALENs transgenic mice were generated by microinjecting the vector pCAG-R4-IRES-L4 into the fertilized eggs of C57BL/6 dams. Of the 25 newborn pups, 5 carried the TALENs DNA. The genotypes were analysed by PCR as well as by Southern blot (Figure 2A and Figure S1A ). Single integration site was found in four of the five transgenic founders (Table S5) , while we failed to identify the definite integration site in the remaining transgenic mouse. Expression of TALENs in the transgenic mice was detected by RT-PCR, and one mouse (F0-5) showed a higher expression level than the others ( Figure S1B ). TALENs + /β 654 mice was then generated by mating the TALENS transgenic founders with β 654 -thalassaemia mice.
Double heterozygous mice were determined by PCR analysis of tail genomic DNA ( Figure 2B ), and the transgene transmission to the offspring is summarized in Table S6 . To further investigate the activity of TALENs in vivo, PCR amplified fragments of the HBB IVS2-654 site from TALENs + /β 654 mice were cloned using TA cloning, and followed by Sanger sequencing ( Figure 2C ). 
| D ISCUSS I ON
The β 654 -thalassaemia consists of one of the most common types of β-thalassaemia in China, accounting for almost 17%-36% of the total β-thalassaemia alleles in the Chinese population. 33 Moreover, CRISPR/Cas9 is limited by the requirement for a PAM (NGG) sequence, and the proper sgRNAs that can directly target to the HBB IVS-2-654 mutation site was difficult to obtain. Therefore, TALENs represent an interesting alternative to CRISPR/Cas9 approaches in our study, as it can directly target our interesting mutant site and reduces the potential off-target events.
In our study, we analysed the ten most potential off-target sites of TALENs predicted by widely accepted bioinformatics tool. No offtarget event was detected, which was consistent with another study using TALENs to correct HBB IVS-2-654 mutation in patient-specific iPSCs. 15 With limitation of the current knowledge of TALENs and possible unknown defects of the system, we cannot completely exclude the possibility of the existence of other off-target events.
Further exploration of the correlating studies in human or their disease cells would be valuable to investigate the off-target events before TALENs can be used in clinical application in the future.
Nucleases facilitating homologous recombination in iPSCs
or HSPCs were used to correct single-nucleotide mutations. [15] [16] [17] However, the low efficiency of HDR hindered their further application in pursuit of an effective therapy. proposes that TALENs-mediated deletion of HBB IVS2-654 mutation site has great potential to efficiently alleviate the thalassaemia symptoms in patients.
In summary, our study showed that TALENs-mediated deletion of HBB IVS2-654 mutation site has great potential to efficiently alleviate the thalassaemia symptoms, and continuous optimization of the nucleases to eliminate the potential risks such as off-target effect and insertion mutagenesis is needed before their clinical application.
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